Oral administration of rapamycin and cyclosporine differentially alter intestinal function in rabbits.
The immunosuppressive drugs rapamycin (Rap) and cyclosporine A (CsA) are used clinically to modify or abolish immune-mediated functions. This study examined the effect of orally administered regimens of Rap, CsA, and a combination of Rap/CsA on intestinal function in male New Zealand white rabbits. Animals received oral doses of CsA (15 mg/kg/body weight/day), low-dose (LD) and high-dose (HD) Rap (0.25 or 1 mg/kg/body wt/day, respectively), or Rap/CsA (0.25 and 5 mg/kg/body wt/day, or 0.5 and 5 mg/kg/body wt/day, respectively) for 20 days. We measured in vitro uptake of nutrients and permeability, and morphometric measurements in the jejunum and ileum were made. Animals receiving HD-Rap or HD-Rap/CsA had decreased food intake, body weight, and intestinal weight, when compared with LD-Rap, LD-Rap/CsA, CsA, or controls. The maximal transport rate (Vmax) for the active jejunal uptake of D-glucose was increased in HD-Rap and CsA, but not in the HD-Rap/CsA-treated animals. The jejunal Vmax of D-glucose in the LD-Rap- or -Rap/CsA-treated animals was no different from controls. In the HD-Rap- and HD-Rap/ CsA-treated animals, jejunal rates of uptake of stearic, linoleic, and linolenic acids were reduced when compared with controls. Jejunal and ileal permeability (as assessed by the passive uptake of L-glucose, tissue conductance, and mucosal-to-serosal flux of [3H]inulin) was increased in animals treated with HD-Rap or HD-Rap/CsA, when compared with CsA or controls. These parameters of permeability were no different at lower doses of Rap or Rap/CsA. The jejunal and ileal villous surface area was increased in CsA, but decreased in HD-Rap or HD-Rap/CsA animals. Thus, HD-Rap given alone or in combination with CsA reduced body weight gain, in part due to reduced food intake and malabsorption of lipids, which was due at least in part to reduced intestinal surface area. The relevance of these findings to patients undergoing chronic immunosuppressive drug therapy needs to be established.
Dias
V C
VC
Department of Laboratory Medicine, University of Alberta, Edmonton, Canada.
Madsen
K L
KL
Mulder
K E
KE
Keelan
M
M
Yatscoff
R W
RW
Thomson
A B
AB
D000284:Administration, Oral; D000818:Animals; D002784:Cholesterol / Q000493:pharmacokinetics; D016572:Cyclosporine / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005227:Fatty Acids / Q000493:pharmacokinetics; D005632:Fructose / Q000493:pharmacokinetics; D005947:Glucose / Q000493:pharmacokinetics; D007082:Ileum / Q000187:drug effects / Q000502:physiology; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007408:Intestinal Absorption / Q000187:drug effects; D007422:Intestines / Q000187:drug effects* / Q000502:physiology*; D007583:Jejunum / Q000187:drug effects / Q000502:physiology; D008297:Male; D010539:Permeability / Q000187:drug effects; D011817:Rabbits; D020123:Sirolimus / Q000008:administration & dosage*
D005227:Fatty Acids; D007166:Immunosuppressive Agents; D005632:Fructose; D016572:Cyclosporine; D002784:Cholesterol; D005947:Glucose; D020123:Sirolimus